التفاصيل البيبلوغرافية
| العنوان: |
Brentuximab vedotin, nivolumab, doxorubicin, and dacarbazine for early‐stage classical Hodgkin Lymphoma: Updated results from an ongoing phase 2 study (SGN35‐027 Part C). |
| المؤلفون: |
Abramson, J. S., Straus, D., Bartlett, N., Burke, J. M., Lynch, R. C., Domingo‐Domenech, E., Hess, B., Schuster, S., Linhares, Y., Ramchandren, R., Gandhi, M., Mowat, R., Shah, H., Jurczak, W., Re, A., Hahn, U., Prince, H. M., Ho, L., Guo, W., Jain, S. |
| المصدر: |
Hematological Oncology; Jun2023 Supplement 1, Vol. 41, p353-355, 3p |
| مصطلحات موضوعية: |
HODGKIN'S disease, NIVOLUMAB, DACARBAZINE, DOXORUBICIN |
| مستخلص: |
Three percent of pts discontinued treatment (all study drugs) because of treatment-emergent adverse events (TEAEs). Herein, we present updated efficacy and safety results from an ongoing phase 2 study of a novel combination of BV + nivolumab with doxorubicin and dacarbazine among pts with early-stage cHL (SGN35-027 Part C). B Introduction: b Brentuximab vedotin (BV) and nivolumab are well tolerated, active treatments for patients (pts) with classical Hodgkin lymphoma (cHL) (Advani 2021; Yasenchak 2020). [Extracted from the article] |
|
Copyright of Hematological Oncology is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
Full Text Finder